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ABSTRACT: With the spread of drug resistance, new antimicrobials are urgently needed. Here, we
set out to tackle this problem by high-throughput exploration for novel antifungal synergies among
combinations of approved, nonantifungal drugs; a novel strategy exploiting the potential of alternative
targets, low chemicals usage and low development risk. We screened the fungal pathogen Candida
albicans by combining a small panel of nonantifungal drugs (all in current use for other clinical
applications) with 1280 compounds from an approved drug library. Screens at sublethal concentrations
of the antibiotic paromomycin (PM), the antimalarial primaquine (PQ), or the anti-inflammatory drug
ibuprofen (IF) revealed a total of 17 potential strong, synergistic interactions with the library
compounds. Susceptibility testing with the most promising combinations corroborated marked
synergies [fractional inhibitory concentration (FIC) indices ≤0.5] between PM + β-escin, PQ +
celecoxib, and IF + pentamidine, reducing the MICs of PM, PQ, and IF in C. albicans by >64-, 16-, and
8-fold, respectively. Paromomycin + β-escin and PQ + celecoxib were effective also against C. albicans biofilms, azole-resistant
clinical isolates, and other fungal pathogens. Actions were specific, as no synergistic effect was observed in mammalian cells. Mode of
action was investigated for one of the combinations, revealing that PM + β-escin synergistically increase the error-rate of mRNA
translation and suggesting a different molecular target to current antifungals. The study unveils the potential of the described
combinatorial strategy in enabling acceleration of drug-repurposing discovery for combatting fungal pathogens.
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Fungal pathogens have emerged as a leading cause ofhuman mortality. Recent estimates suggest that invasive
fungal infections are associated with mortality rates ∼50% in
hospitalized patients and are killing over 1.6 million people
annually, more than major diseases such as malaria and breast
cancer.1,2 The striking impact on human health is due partly to
a limited number of approved antifungal drugs and the
emergence of resistance to those current treatments.2 The lack
of antifungals can be ascribed at least partly to the conservation
of eukaryotic gene functions between fungi and humans,
making drug discovery challenging.3 Echinocandins are the
most recent class of antifungals, but it has been 14 years since
the last echinocandin, anidulafungin, was introduced to the
market.4
Combinatorial inhibition of fungal growth provides an
attractive strategy to help control fungal diseases. Drug
combinations can allow use of decreased doses of each
compound compared to monotherapy, potentially lowering
costs and toxicity,5−7 especially where the agents act
synergistically, i.e., with a combined effect greater than that
expected from the individual drug effects. For example, a
synergistic combination consisting of amphotericin B and 5-
flucytosine is used to treat cryptococcosis.8
The repurposing of existing, approved drugs for alternative
uses as antifungals has emerged as a further approach to
facilitate drug development.3,9−11 A key advantage is that
information on toxicology and pharmacokinetics from
preclinical and clinical trials is already available, lowering
regulatory barriers, development time, and cost. Recent studies
identified drugs in FDA-approved libraries that could enhance
efficacy of current antifungal drugs, such as fluconazole,
caspofungin, and amphotericin B, against Candida and
Cryptococcus spp.9,10 Chemical genetic analysis showed that
these chemicals belonged to two classes of compounds, which
either perturbed membrane permeability or inhibited sphingo-
lipid biosynthesis.9,10 However, resistance is already well
documented for the antifungal drugs cited above, with
potential for cross-resistance also to agents (possibly
synergistic) that act at a related target, undermining the
potential long-term value of combinations involving these
agents. Therefore, combinations of agents where neither is a
current antifungal could have particular value as a future
antifungal strategy. The use of chemosensitizers (i.e.,
compounds that further sensitize cells to the effects of a
bioactive agent) to potentiate the effect of a nonantifungal
drug has shown promising results.12 Here, we developed a
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screening strategy to identify compounds from large libraries of
approved drugs that could act in synergy with common
nonantifungal drugs. For the latter, to establish proof-of-
principle we used the aminoglycoside antibiotic paromomycin
(PM), the antimalarial primaquine (PQ), and the nonsteroidal
anti-inflammatory drug ibuprofen (IF). We report character-
ization of new drug combinations which synergistically and
selectively target key fungal pathogens, including via novel
mode of action. The results indicate a promising alternative
strategy for targeting fungal pathogens by high-throughput
exploration of combinatorial drug repurposing. By excluding
current antifungal therapeutics, application of such an
approach should also reduce selection for extant resistance,
prolonging longevity of current antifungals.
■ RESULTS
Compounds from the Approved Drug Library
Potentiate Action of Three Nonantifungal Drugs
against C. albicans. A screen was performed against
C. albicans with the Prestwick library (PL) of FDA-/EMEA-
approved drugs in the absence and presence of subinhibitory
concentrations of a small panel of exemplar nonantifungal
drugs: paromomycin, PM; primaquine, PQ; ibuprofen, IF
(Figure 1A). The latter three drugs are themselves approved
and used widely for different applications in humans. In
addition, they have different modes of action, so broadening
the scope for finding diverse chemical interactions in the
screens. We also know from previous studies that those three
drugs exhibit some antifungal activity but at concentrations,
when supplied alone, not normally suitable for therapeutic
purposes.13−15 The three agents are therefore ideal candidates
for finding new combination-synergies that could enable
therapeutic applications. Library compounds were supplied at
100 μM, the maximum concentration attainable while ensuring
that the added volumes of drug stock solutions (in DMSO) did
not exceed 2% of final volume. At this concentration, ∼90% of
the compounds had minimal growth effects when supplied
alone (i.e., less than 20% reduction of growth) (Figure 1A;
Table S1); therefore, this concentration was suitable for
identifying strong enhancers of the three compounds of
interest. Effect strength was calculated for each combination
(see Materials and Methods) and those with an effect strength
>50 were considered as combinations of interest, i.e., where
the difference between % growth with the PL compound alone
and the combination was >50. From the 1280 PL compounds
screened, 1, 14, and 2 showed an effect strength >50 when
Figure 1. Chemical screening data for compounds that potentiate three nonantifungals in C. albicans. PL compounds were supplied at 100 μM. (A)
The scatterplots show the normalized growth of C. albicans for each PL compound in the absence (x axis) and presence of either PM, PQ, or IF (y
axis). The data are means from duplicate screens. The full screen data are in Table S1. (B) Effect strength of the different combinations; those that
showed an effect strength >50 are colored in pink in A. (C) The names and structures of library compounds giving the greatest effect strength from
each screen.
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combined with PM, PQ, and IF, respectively; these also
showed less than 30% reduction of growth when supplied
alone (Figure 1A,B; Table S1). The most promising library
compound (i.e., giving the highest effect strength) for each of
the three nonantifungal drugs was selected for further tests, i.e.,
β-escin (for PM), celecoxib (PQ), and pentamidine (IF)
(Figure 1C).
The Drug Combinations Have Synergistic, Fungici-
dal, and Antibiofilm Actions in C. albicans. Checkerboard
analysis was performed with C. albicans to corroborate
synergistic interactions for the most promising drug combina-
tions identified from the screens. Each of these three
combinations was found to give synergistic inhibition of
C. albicans growth. The combination decreased the minimum
Figure 2. Lead combinations from the screens inhibit C. albicans synergistically. (A) Checkerboard assays of drug−drug interactions. Two-fold
serial dilutions of the PL compounds were combined with 2-fold dilutions of the three nonantifungal drugs. Growth (OD600) was measured after 24
h and values obtained with agents expressed as percentages relative to the minus-drug controls. Data are means from at least three independent
experiments. FICI, fractional inhibitory concentration index. (B) Cidal and static drug interactions. After 24 h, cells from the checkerboard assays
were spotted onto YPD agar without drugs and incubated for 24 h at 30 °C before plates were photographed. The images are representative of
three independent experiments.
Table 1. Library Compound Chemical Interactions with the Nonantifungals in C. albicans
planktonic cells of indicated strains biofilm
SC5314 J942148 J980280 SCS1192299X SC5314
Paromomycin (PM) and β-escin (βE) MIC PM (mM) >81.2 >81.2 1.27 1.27 >81.2
CIC PM (mM) 1.27 2.54 0.32 0.32 20.3
MIC βE (μM) 500 >500 500 500 >500
CIC βE (μM) 62.5 62.5 125 125 125
FICI ∼0.13a <0.08 0.5 0.5 <0.25
Primaquine (PQ) and Celecoxib (CC) MIC PQ (mM) 5 2.5 2.5 2.5 5
CIC PQ (mM) 0.31 0.63 0.16 0.31 1.25
MIC CC (mM) >5 >5 2.5 2.5 >5
CIC CC (mM) 0.63 1.25 0.31 0.31 1.25
FICI 0.06−0.13 0.25−0.38 0.19 0.5 0.25−0.38
Ibuprofen (IF) and Pentamidine (PD) MIC IF (mM) 4.36 4.36 2.18 2.18 >4.36
CIC IF (mM) 0.55 0.55 0.55 0.27 1.09
MIC PD (μM) 1000 250 31.25 62.5 1000
CIC PD (μM) 125 31.25 0.98 15.63 1000
FICI 0.25 0.25 0.28 0.38 1−1.13
aDrug interactions in planktonic cells and 24 h old biofilms were determined by checkerboard assays (see Materials and Methods). MIC, minimum
inhibitory concentration. CIC, combination inhibitory concentration, the lowest inhibitory concentration of the agent achieved when in the
combination. FICI, fractional inhibitory concentration index.
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Table 2. Library Compound Chemical Interactions with the Nonantifungals in Several Fungal Pathogens and in Mammalian
Cells
Aspergillus fumigatus Candida glabrata Cryptococcus neoformans mammalian cells
Paromomycin (PM) and β-escin (βE) MIC PM (mM) >81.2 10.2 0.16 81.2
CIC PM (mM) 40.6 2.54 − 40.6
MIC βE (μM) >500 250 >500 40
CIC βE (μM) 125 62.5 − 10
FICI <0.38a 0.5 − 0.75
Primaquine (PQ) and Celecoxib (CC) MIC PQ (mM) >10 10 0.63 0.1
CIC PQ (mM) 5 1.25 0.08 0.1
MIC CC (mM) >5 >5 2.5 0.125
CIC CC (mM) 0.16 0.31 0.63 0.125
FICI <0.27 0.13−0.16 0.38 2
aDrug interactions were determined by checkerboard assays (see Materials and Methods). MIC, minimum inhibitory concentration. CIC,
combination inhibitory concentration, the lowest inhibitory concentration of the agent achieved when in the combination. FICI, fractional
inhibitory concentration index.
Figure 3. β-Escin does not increase PM-SFX uptake. (A) Synthesis of paromomycin-SFX. (B) Determination of inhibitory drug concentrations:
S. cerevisiae was cultured in YPD with agents supplied at the specified concentrations. (C) Determination of PM-SFX uptake kinetics: Cells were
incubated with PM-SFX at the indicated concentrations, and cellular PM-SFX determined at intervals with flow cytometry. Values shown are after
subtraction of autofluorescence determined in cells incubated without PM-SFX. (D) Test of β-escin effect on PM-SFX uptake: S. cerevisiae was
incubated for 20 min with 81 μM PM-SFX in combination or not with 50 μM β-escin. AU, arbitrary units. All values are means ± SEM from three
independent determinations.
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inhibitory concentrations (MICs) of the individual agents by
>64-fold for PM, 16-fold for PQ, and 8-fold for IF, with
fractional inhibitory concentration indices (FICI; see Materials
and Methods) of ∼0.13 for PM + β-escin, between 0.06 and
0.13 for PQ + celecoxib, and 0.25 for IF + pentamidine (a
combination is considered synergistic when the FICI is ≤0.5)
(Figure 2A and Table 1).
Resistance among clinical fungal isolates has eroded the
efficacy of current antifungals such as azoles, but resistance is
typically less common against fungicidal than fungistatic
compounds.16 The present data indicated that PM + β-escin
and PQ + celecoxib are fungicidal, as C. albicans cells showing
growth inhibition in the checkboard assays proved unable to
form colonies when recovered to the control medium (Figure
2B). In contrast, IF + pentamidine was fungistatic.
Candida albicans has the ability to form drug-resistant
biofilms, associated with high mortality rates in infected,
immunocompromised patients.17 We tested the impact of the
combinations against 24 h old biofilm structures formed in 96-
well microtiter plates. Biofilm metabolic activity was synergisti-
cally decreased with the combinations PM + β-escin and PQ +
celecoxib, albeit with slightly higher FICI values compared to
planktonic C. albicans SC5314 (Table 1). However, no
synergistic effect (FICI > 0.5) was observed with IF +
pentamidine, suggesting a different interaction only for this
particular combination when treating biofilms compared to
planktonic cells. Whereas we tested preformed biofilms, the
fact that planktonic cells are affected by the combinations
means that the formation of biofilms should also be inhibited
(while we have no reason to expect that a particular step in the
formation of biofilms should specifically be targeted by these
combinations, e.g., adherence).
The Library Compounds Enhance the Effects of
Paromomycin, Ibuprofen, and Primaquine in Azole-
Resistant C. albicans Isolates and in Other Fungal
Pathogens. We evaluated the activity of the combinations
against three azole-resistant clinical isolates.18 Certain of the
clinical isolates showed differences in sensitivity to individual
agents compared with the laboratory strain C. albicans SC5314.
Moreover, as in the SC5314 strain, synergies were observed
with each of the test combinations for all of the azole-resistant
isolates (FICI ≤ 0.5) (Table 1).
To indicate the spectrum of synergy against other fungal
pathogens, the most promising combinations PM + β-escin
and PQ + celecoxib (both were fungicidal and active against
biofilms), were tested against other key fungal species. It was
not possible to determine high MICs for certain drugs and
species, as the amounts of solvent added would have been
inhibitory. This precluded estimation of FICI for the PM + β-
escin combination in Cryptococcus neoformans. Nevertheless,
synergistic inhibition by this combination could be demon-
strated on the growth of Aspergillus fumigatus and Candida
glabrata, and synergy of the PQ + celecoxib combination was
evident against all three pathogens (Table 2). The strongest
effect for PM + β-escin was obtained against A. fumigatus
(FICI < 0.38). The strongest synergy for PQ + celecoxib was
with C. glabrata (FICI 0.13−0.16), giving striking reductions
of the MICs when in combination (8-fold for PQ and >16-fold
for celecoxib). FIC indices were lower for both combinations
with C. albicans (Table 1). However, C. glabrata and
C. neoformans were more sensitive to PM and β-escin, and
PQ and celecoxib, respectively, than C. albicans.
To assess specificity of synergy for the fungi, we also tested
mammalian cells. The synergy appeared to be specific to the
fungi as no synergy was detectable with NIH 3T3 cells, which
showed FICI indices of 0.75 for PM + β-escin and 2.0 for PQ +
celecoxib (Table 2). We also tested the combination PM + β-
escin against TE671 cells using subinhibitory concentrations of
each drug. No significant difference in cell viability was
observed between the cells treated with β-escin alone and the
cells treated with the combination (Figure S2) supporting the
absence of combinatorial cytotoxicity.
The β-Escin and Paromomycin Combination Pro-
motes Synergistic Loss of Translation Fidelity. β-Escin is
the major active component in extracts of horse chestnut seeds
and has been reported to show certain antifungal proper-
Figure 4. Paromomycin and β-escin synergistically increase mistranslation rate. (A) S. cerevisiae transformed with a dual-luciferase plasmid
encoding the Renilla and firefly luciferases separated by a UAA stop codon (left) or containing a His245→ Arg245 mutation in the firefly luciferase
gene (right) were exposed to 50 μM β-escin or 8.1 μM PM alone or in combination for 16 h before determination of the two luciferase activities.
The values are means ± SEM from at least three independent experiments. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 according to multiple
comparisons (Tukey’s test) by one-way ANOVA; ns, not significant. Values were normalized for incidental variation in assay sensitivity between
replicate experiments performed on different days. (B) S. cerevisiae containing a plasmid encoding a RFP and a nonfunctional Tyr66 → His66 GFP
were treated with 30 μM β-escin or 20.3 or 40.6 μM PM, alone or in combination for 16 h before cell fluorescence was measured by flow
cytometry. Cells expressing GFP are shown as percentages of total cells. The values are means ± SEM from three independent experiments. **p ≤
0.01, ****p ≤ 0.0001 according to multiple comparisons (Tukey’s test) by two-way ANOVA.
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ties.19,20 The compound interacts with sterol molecules
creating pores in the cell membrane.21 Paromomycin is
known to cause mRNA mistranslation. Previously, drug
combinations involving PM have been reported to increase
further the rate of translation error.13,22 We hypothesized that
the PM + β-escin mode of synergistic action could arise from
β-escin allowing increased cellular entry of the aminoglycoside,
leading to an increase in the error-rate of mRNA translation.
To test this hypothesis, PM was tagged with the fluorescent
probe SFX, a fluorescein analogue with a seven carbon spacer
to ensure retention of fluorescence following conjugation
(Figures 3A, S1). The addition of the SFX label to the drug did
not affect the antifungal interaction, as PM-SFX still acted in
synergy with β-escin on yeast growth (Figure 3B);
Saccharomyces cerevisiae was used for these experiments as a
range of mistranslation-assay tools are available with this model
yeast (we first confirmed β-escin synergy with non-SFX labeled
PM in S. cerevisiae). Yeast cells were treated with 81 μM PM-
SFX alone or in combination with 50 μM of β-escin for 20 min
(Figure 3C) before cellular SFX fluorescence was measured by
flow cytometry. No significant increase in PM-SFX uptake was
observed in the presence of β-escin treatment (Figure 3D),
suggesting elevated PM uptake was not responsible for the
synergy observed between these compounds.
To test whether synergistic growth inhibition was reflected
by synergistic mistranslation, we used quantitative assays of
mistranslation. These included tests for readthrough of a UAA
stop codon positioned between Renilla and firefly luciferase
ORFs, or for amino acid misincorporation in firefly luciferase.
The PM + β-escin combination increased the rate of stop
codon readthrough and missense error significantly compared
to both of the individual drug effects, with a stronger effect on
missense than stop codon readthrough (Figure 4A). We also
measured misincorporation rate in a strain expressing a
nonfunctional GFP (Tyr66 → His66), constructed as part of
this study. Significant restoration of cellular GFP fluorescence
was observed when the cells were treated with the drug
combination compared to no drug, or either drug alone
(Figure 4B). The data suggest that β-escin synergistically
potentiates the action of PM on translation fidelity and this
effect is not due to increased PM uptake.
■ DISCUSSION
This study proposes an alternative combinatorial strategy for
combatting fungal pathogens, by high-throughput exploration
for novel antifungal synergies among pairs of approved drugs
not currently useful for treating fungal infections and with
diverse modes of action. We show that the approach
successfully enables discovery of new, potent synergies. This
strategy opens a potential treasure-trove of novel antifungal
treatment-options, by exploiting the principle of drug synergy
in a drug repurposing context.
High-throughput combinatorial antifungal screens have
previously included at least one existing antifungal drug. For
instance, by combining six known antifungals and fungicides
with more than 3600 compounds in fungal species including
C. albicans, a diverse range of chemical−chemical interactions
were recently described. Eighteen compounds increased the
susceptibility of a wild type strain of C. albicans to
fluconazole.10 However, only three were synergistic with the
azole against fluconazole-resistant clinical isolates,10 suggesting
a limitation in using available antifungals for chemical
screening as it is likely that existing resistance diminishes the
effectiveness of the combinations. With increased recrudes-
cence of fungal isolates resistant to the current arsenal of
antifungals, new drugs with new mechanisms of action are
needed. Nonantifungal drugs could therefore be repositioned
as novel antifungal agents. Numerous drugs may affect fungal
growth, but usually only at concentrations so high as to exclude
them from therapeutic use for this purpose. One approach to
achieving inhibition at lower doses is by using chemo-
sensitizers. Chemosensitizing compounds possess antifungal
activity, but at insufficient potency to serve alone. Their main
modes of action are disruption of the fungal stress response,
destabilization of the structural integrity of cellular and
vacuolar membranes or stimulation of reactive oxygen species
production making cells more sensitive to the effects of
treatment.23 Bithionol, which is known to target antioxidant
defense, has proven effective in combination with pro-oxidant
chemosensitizers against the fungal pathogen A. fumigatus.12
Another strategy is by exploiting synergies between pairs of
drugs; such synergies may arise where two active agents target
any common process but by different mechanisms or
pathways.13,22,24,25 A novel aspect of the present work is that
we selected three nonantifungal approved drugs (i.e.,
paromomycin, primaquine, and ibuprofen) with distinct
modes of action, to search for novel antifungal synergies in
combinations with 1280 FDA-/EMEA-approved drugs. Prior
approval of these off-patent agents are features that can help
expedite development toward clinical application of potential
hits.
Among 17 synergies identified from ∼3840 interactions
tested, three were selected for further study. β-Escin enhanced
the effect of PM, producing a striking >64-fold decrease of the
MIC of PM, the strongest decrease observed in this study.
Further checkerboard assays over lower concentration ranges
of the antibiotic showed that the MIC of PM could be
decreased even further: to 812 μM and ∼49 μM when
combined with 62.5 μM and 125 μM β-escin, respectively
(both subinhibitory concentrations) (Figure S3). The MIC
range of PM in E. coli is from 3 to 208 μM (0.002−0.128 mg
mL−1).26 The current dosing of PM in humans ranges from
topical creams for cutaneous action through to intramuscular
injections for systemic therapy and, for the latter, doses of 20
mg−1 kg−1 day−1 have been employed, resulting in plasma
concentrations of ∼10 μg mL−1.27 This corresponds to PM
concentrations of ∼20 μM, and this level of drug in the plasma
is retained for several hours. Therefore, the effective
paromomycin concentrations when in combination are within
the range that could be considered for (antifungal) therapeutic
use, although a full human pharmacokinetics study of both
drugs in combination would be required to establish the
definitive therapeutic doses needed for synergism. We showed
that the two drugs synergistically increase the rate of error in
mRNA translation. Protein synthesis is an essential process and
therefore can be an important drug target. The β-escin
mechanism of action in this combination remains unclear, as it
did not cause increased PM uptake. Recent studies indicated
that β-escin has mistranslation (readthrough) activity of its
own in mammalian cells.28,29
Another combination of interest characterized here
comprised the antimalarial primaquine and the nonsteroidal
anti-inflammatory drug (NSAID) celecoxib. It has been shown
that PQ can target key iron−sulfur cluster proteins in yeast,
such as aconitase, required for the tricarboxylic acid (TCA)
cycle.15 Interestingly, the celecoxib derivative AR-12 was found
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00405
ACS Infect. Dis. 2020, 6, 2950−2958
2955
to inhibit fungal acetyl-COA synthetase in vitro and has
activity against a range of pathogenic yeasts and molds.30,31
Acetyl coenzyme A is a crucial metabolite for fungal
metabolism including in the TCA cycle, suggesting one
potential target of the synergy between PQ and celecoxib.
Another NSAID cyclooxygenase inhibitor, ibuprofen, was a
subject of this study. As ibuprofen targets mitochondria32 its
synergistic inhibition of fungal growth when combined with
the antibiotic pentamidine is not unexpected, as pentamidine is
known to inhibit translation in yeast mitochondria.33
A decreased risk of resistance emergence against synergistic
drug combinations should be marked when agents have
fungicidal rather than fungistatic actions.16,34,35 Paromomycin
+ β-escin and primaquine + celecoxib combinations described
here had fungicidal activity. Furthermore, these also showed
efficacy against C. albicans biofilms, which typically have
elevated resistance to antifungals.17 As well as being effective
against a standard laboratory strain of C. albicans, these
combinations also synergistically inhibited growth of azole-
resistant clinical isolates and of other major fungal pathogens
(A. fumigatus, C. glabrata, and C. neoformans), indicating broad
spectrum actions of the type that can be advantageous in
clinical use. Importantly, synergy was not recapitulated in
mammalian cells, suggesting specificity for the fungi and
consistent with the possibility of therapeutic applications.
The high-throughput strategy developed here successfully
identified several novel antifungal synergies and could help
bypass current antifungal resistances, from screens that were by
no means exhaustive. It suggests that a much wider potential
arsenal of antifungal activities are attainable with this approach.
This is important considering the urgent, unmet need for new
therapeutic antifungal options.
■ MATERIALS AND METHODS
Strains, Culture, and Maintenance. Pathogenic organ-
isms used in this study were the yeasts Candida albicans
SC5314 and the azole-resistant isolates J942148, J980280, and
SCS1192299X (kindly provided by Carol Munro and Donna
MacCallum, University of Aberdeen, UK), Cryptococcus
neoformans 1841, Candida glabrata BG2, and Aspergillus
fumigatus CBS 144.89. Mode of action studies were performed
with Saccharomyces cerevisiae BY4743 (MATa/α his3Δ1/
his3Δ1 leu2Δ0/leu2Δ0 LYS2/lys2Δ0 met15Δ0/MET15
ura3Δ0/ura3Δ0). The fungi were maintained and grown in
either YPD medium [2% peptone (Oxoid), 1% yeast extract
(Oxoid), 2% D-glucose], YNB medium [0.69% yeast nitrogen
base without amino acids (Formedium), 2% D-glucose,
supplemented with amino acids or nucleobases as appropriate
for plasmids selection],36 potato dextrose agar or broth [PDA
(Oxoid) or PDB (Sigma)], or RPMI 1640 + 2% glucose
medium (Sigma). Where necessary, media were solidified with
1.5% agar (Sigma).
High-Throughput Screening. The Prestwick Chemical
Library (PL) (Prestwick Chemical) was screened with drugs
supplied at a final concentration of 100 μM in the presence or
absence of either 812 μM (500 μg mL−1) paromomycin
sulfate, 750 μM (342 μg mL−1) primaquine biphosphate, or
436 μM (90 μg mL−1) ibuprofen (Sigma). (Among the PL
drugs that gave synergies from the screens, 100 μM
corresponds to 113 μg mL−1 β-escin, 38 μg mL−1 celecoxib,
and 59 μg mL−1 pentamidine.) Screens were performed in
duplicate using C. albicans, inoculated from YPD plates to YPD
broth and cultured overnight at 30 °C, 120 rev. min−1.
Overnight cultures were diluted to OD600 0.5 and cultured for
a further 4 h in fresh YPD before dilution of these experimental
cultures to OD600 0.01 in the same medium. Aliquots (100 μL)
of the diluted culture plus any chemical supplements (see
above) were transferred to 96-well plates (Greiner Bio-One)
and cultured for 24 h at 30 °C, 120 rev. min−1, with OD600
measured at 24 h in a BioTek EL800 microplate spectropho-
tometer. OD600 was expressed as percentage of growth relative
to control growth (i.e., without any chemicals). Effect strength
[(% growth with PL agent) − (% growth with PL agent +
second agent)] was calculated for each combination; screen
hits were considered as those agents showing an effect strength
>50.
Growth Inhibition, Toxicity, and Checkerboard
Assays. General culturing and preparation for checkerboard
assays adhered to EUCAST guidelines,37 with the exception
that YPD broth was used here to validate the data from the
screens. Briefly, either yeast cells from single colonies or
A. fumigatus spores were inoculated from 2-d PDA plates to
YPD broth adjusted to a final concentration of 105 cells or
spores mL−1. Culture aliquots (100 μL) were transferred to 96-
well microtiter plates with chemicals added at the specified
concentrations. The inoculated plates were incubated statically
for 24 (C. albicans and C. glabrata) or 48 (C. neoformans and
A. fumigatus) hours at 30 °C (yeasts) or 37 °C (A. fumigatus).
OD600 was then measured with a BioTek EL800 microplate
spectrophotometer. Fractional inhibitory concentration index
(FICI) was calculated as an indicator of synergy.38 Assays for
fungicidal or fungistatic activity were as described previously.22
Immortalized NIH 3T3 mouse embryonic fibroblast and
human TE671 (rhabdomyosarcoma RD cell line) cells
(passage 25) were cultured and toxicity to the cells was
assayed (using the CCK-8 reagent; Sigma) as described
previously.13 All the assays were performed in independent
triplicates.
Biofilm Inhibition Assays. Biofilm metabolic activity was
measured by the XTT (tetrazolium salt, 2,3-bis[2-methyloxy-4-
nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) (Sigma)
reduction assay and performed as described previously.18,22
Briefly, overnight C. albicans cultures were diluted to OD600 ∼
0.01 in RPMI 1640 medium and 100 μL aliquots transferred to
96-well microtiter plates (Greiner Bio-One). After removing
nonadherent cells, yeasts were incubated at 37 °C for 24 h in
fresh medium. Biofilms were then washed with PBS and drugs
added as specified. Cultures were incubated for a further 24 h,
then the biofilm was washed and the XTT reaction performed
using 210 μg mL−1 XTT and 4.2 μM menadione. Biofilm
metabolic activity was measured after 3 h at 490 nm using a
BioTek El800 microplate spectrophotometer. The assays were
performed in independent triplicates.
Mistranslation Assay. For quantitative determination of
mistranslation, S. cerevisiae BY4743 was transformed using the
lithium acetate method39 with a dual luciferase reporter
plasmid encoding firefly and Renilla luciferases either separated
by a UAA stop codon40 or containing a missense codon in the
ORF encoding firefly luciferase (His245 → Arg245)41 (kindly
provided by D. Bedwell, University of Alabama, USA) as well
as with a dual fluorescence reporter plasmid encoding GFP and
RFP in frame (kindly provided by N. Altamura, Institute of
Biomembranes and Bioenergetics, National Researches Coun-
cil, Bari, Italy)42 and containing a missense codon in the ORF
encoding GFP (Tyr66 → His66). In the latter case, the
missense codon was introduced here by replacing Tyr66 with a
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histidine codon by site-directed mutagenesis, using the Q5 kit
(New England BioLabs) with a plasmid containing the GFP
and RFP separated by a CAA sense codon42 as DNA template.
Precultures were prepared as described previously.13 Then, the
cultures were diluted to OD600 0.01 in YNB medium, 100 μL
aliquots were transferred to 96-well microtiter plates, and the
drugs were added as specified in the Results. Plates were
incubated at 30 °C for 16 h with shaking in a BioTek Epoch 2
microplate spectrophotometer. For the dual luciferase assays,
cell extracts were prepared and luciferase activities were
measured as described previously.13 For the dual fluorescence
assays, cells were harvested by centrifugation and resuspended
in 500 μL PBS before analysis of GFP and RFP fluorescence
with a Beckman Coulter Astrios cytometer equipped with 488
and 561 nm lasers. The measurements of mistranslation rate
were done in independent triplicates.
Assay of Paromomycin Uptake. To measure PM uptake,
the aminoglycoside was conjugated to SFX [6-(fluorescein-5-
[and-6]-carboxamido) hexanoic acid, succinimidyl ester]
(Invitrogen). Parmomycin sulfate salt (100 mg, 0.14 mmol)
was dissolved in a 6 mL solution of H2O:MeOH (2:1 ratio, v/
v). Triethylamine (100 μL) was added to this solution
dropwise and stirred for 12 h. SFX (8 mg, 0.014 mmol)
dissolved in MeOH (0.5 mL) was added dropwise over 15 min
at 0 °C to a solution comprising neutralized paramomycin (8
mg, 0.013 mmol) and 10 μL triethylamine dissolved in
H2O:MeOH (4:1 ratio, v/v). The reaction mixture was stirred
for 2 days and then unreacted dye and trimethylamine were
removed by dialysis for 1 day against water using a 1 kDa
molecular weight cutoff membrane. The purity of the final
product was confirmed to be ≥97% by HPLC (Figure S1).
Precultures and cultures in triplicate of S. cerevisiae were
prepared as described above. Aliquots (10 μL) of cell
suspension (OD600 ∼ 2.0) were incubated with PM-SFX ±
β-escin for 20 min, then washed and resuspended in 500 μL
PBS before fluorescence from cellular PM-SFX was measured
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